VYNE Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference
18 nov. 2022 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo
17 nov. 2022 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
10 nov. 2022 16h01 HE
|
VYNE Therapeutics Inc.
IND clearance received for pan-BD BET inhibitor, VYN201; Anticipate first patient to be enrolled in Phase 1a/b trial for Vitiligo this month Continued progression of discovery and development of...
VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Reports Second Quarter 2022 Financial Results
12 août 2022 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
10 août 2022 08h32 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference
19 juil. 2022 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
17 juin 2022 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., June 17, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference
18 mai 2022 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and...
VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
12 mai 2022 16h05 HE
|
VYNE Therapeutics Inc.
Announced positive Phase 1b data for FMX114 in mild-to-moderate atopic dermatitis Lead BET inhibitor VYN201 demonstrated positive results across multiple preclinical models of inflammation VYNE to...